Regeneron Pharmaceuticals Inc.: clinical-trial pipeline
Regeneron Pharmaceuticals Inc. is the sponsor of 392 clinical trials in ClinicalTrials.gov and the EU CTIS portal; 122 are not yet finished and 12 were first posted in the last 90 days. Source: Arcadium Data, data as of .
Open trials122
Phase 2/3 and 3105
Countries59
New in 90 days12
Trials by phase
| Phase | Trials |
|---|---|
| Phase 1 | 116 |
| Phase 2 | 95 |
| Phase 3 | 94 |
| Phase 1/2 | 34 |
| Not applicable | 30 |
| Phase 4 | 12 |
| Phase 2/3 | 11 |
Trials by status
| Status | Trials |
|---|---|
| Completed | 212 |
| Recruiting | 68 |
| Terminated | 44 |
| Active, not recruiting | 33 |
| Not yet recruiting | 21 |
| Withdrawn or not authorised | 14 |
Condition areas
| Area | Trials |
|---|---|
| Oncology | 107 |
| Immunology and rheumatology | 74 |
| Cardiovascular | 56 |
| Metabolic and endocrine (diabetes, obesity) | 43 |
| Dermatology | 38 |
| Ophthalmology | 33 |
| Respiratory | 23 |
| Haematology | 22 |
| Infectious disease and vaccines | 21 |
| Musculoskeletal | 18 |
| Nephrology and urology | 16 |
| Rare and genetic diseases | 15 |
Countries
| Country | Trials |
|---|---|
| United States | 293 |
| Germany | 80 |
| Spain | 80 |
| Canada | 79 |
| United Kingdom | 79 |
| Poland | 67 |
| France | 66 |
| Belgium | 55 |
| Italy | 54 |
| South Korea | 49 |
| Australia | 48 |
| Japan | 38 |
| Hungary | 34 |
| Netherlands | 34 |
| Taiwan | 31 |
Latest changes
| Day | Change | Trial |
|---|---|---|
| 2026-10-21 | New trial posted | REGN9220 in Combination With Odronextamab in Adult Participants With Relapsed or Refracto… |
| 2026-10-15 | New trial posted | Healthy Adult Participants Trial Comparing Different Cenvacibart Presentations |
| 2026-10-15 | New trial posted | A Study to Evaluate Cenvacibart (REGN7508) for Secondary Stroke Prevention in Adult Parti… |
| 2026-10-07 | New trial posted | Safety and Efficacy Study in Adults With Advanced Solid Tumors Receiving REGN13089-M404-M… |
| 2026-10-06 | New trial posted | Thyroid-Stimulating Hormone Receptor (TSHR) Blockade With REGN24493 in Adult Participants… |
| 2026-10-02 | New trial posted | Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liv… |
| 2026-09-30 | New trial posted | REGN21353 Alone or in Combination With Nezastomig for Metastatic Castration-Resistant Pro… |
| 2026-09-29 | New trial posted | A Phase 3, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety… |
| 2026-09-23 | New trial posted | A Phase 3, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety… |
| 2026-09-22 | New trial posted | A Trial of ALN-6457 in Adult Participants With Symptomatic Prion Disease (PrD) |
| 2026-09-21 | New trial posted | Efficacy and Safety of Olatorepatide Versus Placebo in Adults With Moderate to Severe Hid… |
| 2026-09-09 | New trial posted | A Study Comparing Cemiplimab-based Treatments for Adult Participants With Locally Advance… |
Open trials
The 25 most recently changed open trials.
| Registry id | Title | Phase | Status | Countries |
|---|---|---|---|---|
| NCT06379789 | A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV13… | Phase 1/2 | Recruiting | Australia, Brazil, Canada, Germany +5 |
| NCT06140524 | A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to… | Phase 2 | Recruiting | Belgium, Spain, France, Ireland +3 |
| NCT05785767 | A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for A… | Phase 2/3 | Not yet recruiting | Australia, Canada, Spain, France +9 |
| NCT03888105 | A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgki… | Phase 2 | Active, not recruiting | Australia, Canada, China, Germany +10 |
| NCT06292780 | A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chai… | Phase 1/2 | Recruiting | Germany, Spain, United Kingdom, Greece +4 |
| NCT06369467 | Short-Term Linvoseltamab Treatment on Top of Chronic Dupilumab Treatment for Adults With Severe Immunoglobuli… | Phase 1 | Active, not recruiting | Spain, United States |
| NCT04077099 | A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced No… | Phase 1/2 | Active, not recruiting | France, South Korea, United States |
| NCT05137054 | A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for… | Phase 1 | Recruiting | Spain, France, Greece, Israel +2 |
| NCT03969004 | Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cu… | Phase 3 | Active, not recruiting | Australia, Belgium, Brazil, Canada +12 |
| NCT03564340 | Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Re… | Phase 1/2 | Recruiting | Australia, Belgium, Spain, France +6 |
| NCT05788536 | A Study of DB-OTO, an Adeno-Associated Virus (AAV) Based Gene Therapy, in Children/Infants, Adolescents and A… | Phase 1/2 | Recruiting | Germany, Spain, United Kingdom, Japan +1 |
| NCT03761108 | Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma | Phase 1/2 | Recruiting | Belgium, Germany, Spain, United Kingdom +3 |
| NCT05259709 | A Study of ImmunoPet Imaging Using 89Zr-DFO-REGN5054 in Adult Participants With Solid Cancers Treated With Ce… | Phase 1 | Active, not recruiting | Netherlands |
| NCT06190951 | A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participan… | Phase 2 | Not yet recruiting | Austria, Australia, Canada, Germany +7 |
| NCT02612454 | Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age… | Phase 3 | Active, not recruiting | Canada, Czechia, Germany, United Kingdom +3 |
| NCT06572228 | Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comp… | Phase 4 | Active, not recruiting | Canada, Germany, Denmark, Poland +2 |
| NCT06465329 | A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for… | Phase 2 | Active, not recruiting | Brazil, Germany, Spain, France +1 |
| NCT06161441 | A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than… | Phase 2 | Not yet recruiting | Australia, Chile, Germany, Spain +8 |
| NCT05744921 | A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treat… | Phase 3 | Recruiting | Brazil, Canada, Colombia, Spain +16 |
| NCT05133531 | A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Pat… | Phase 3 | Active, not recruiting | Brazil, Canada, China, Colombia +19 |
| NCT06541704 | A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alon… | Phase 3 | Recruiting | Austria, Australia, Canada, Germany +7 |
| NCT06421636 | A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for… | Phase 2 | Active, not recruiting | United Kingdom, Georgia, Greece, India +4 |
| NCT06848088 | A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma Tre… | Phase 2 | Recruiting | Ireland, United States |
| NCT06975787 | Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis | Phase 1 | Recruiting | Germany, Spain, France, South Korea +2 |
| NCT07015905 | REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults | Phase 3 | Recruiting | Bulgaria, Hungary, Japan, Lithuania +4 |
Hiring for clinical development
Regeneron Pharmaceuticals Inc. has 102 open jobs with a clinical, regulatory, safety, biostatistics or medical-affairs title on its own career sites.
Website: regeneron.com. All sponsors: clinical-trial pipeline by sponsor.
Track a sponsor's pipeline
The API returns the same trials by sponsor website, phase, status, condition and country with a change feed, joined to hiring and public contract awards. Try it without a key on one sponsor.
Sources: ClinicalTrials.gov (U.S. National Library of Medicine, public domain) and the EU Clinical Trials Information System public portal (European Medicines Agency), data as of 2026-10-25. A trial that one register cites in the other is shown once. Organisation-level data only: investigators, contact persons and site names are not stored, and a sponsor that could be a private person is withheld. Sponsor-to-website matches are made by name and can be wrong; check the register before relying on a record. Independent of the NLM, NIH and EMA.
Cite as: Arcadium Data, "Regeneron Pharmaceuticals Inc. clinical trials: 122 open, 105 in phase 3", https://arcadiumdata.io/clinical-trials/sponsor/regeneron-com/, data as of 2026-10-25.